NDAOTICSUSPENSION/DROPS
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1998.
Drug data last refreshed 25m ago · AI intelligence enriched 2h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO HC is a fixed-dose combination otic suspension containing ciprofloxacin hydrochloride (antibiotic) and hydrocortisone (corticosteroid) approved in 1998. It treats acute otitis externa and other ear infections by combining bacterial suppression with anti-inflammatory action. The corticosteroid component works via hormone receptor agonism to reduce inflammation and patient discomfort.
$0.04MPart D
LOE ApproachingProduct is in mature LOE-approaching phase with minimal Part D spending ($40K annually), indicating a niche market with constrained team growth opportunities.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CIPRO HC offers minimal career growth due to zero linked job postings and LOE-approaching lifecycle; roles focus on defensive managed-care strategies, generic preparation, and margin protection rather than expansion. Career value is limited to tactical execution and cost-containment expertise in a declining-revenue environment.
Brand Manager
Worked on CIPRO HC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.